Anew Medical, Inc. (WENA)
Anew Medical, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Omaha, NE, US. The stock last traded at $0.73, down 3.84% on the session, giving a market capitalisation of $15.4M. On trailing twelve-month figures it carries a trailing P/E of 5.19, a net margin of 0.0%. Its beta of 0.02 implies it has historically moved less than the broad market.
Anew Medical, Inc. is a biopharmaceutical firm dedicated to developing innovative treatments for conditions affecting the brain and nervous system, age-related illnesses, and specialized diagnostic tools. Their pipeline includes advanced cell and gene therapies specifically designed to alleviate symptoms of aging-related conditions, such as dementia, Alzheimer's disease, and various neuromuscular disorders. Additionally, Anew Medical is engaged in developing biologics and biosimilars for cancer treatment, alongside research into therapies targeting melanocortin receptors. A key strategic alliance exists with Japan's Okinawa Research Center, focusing on the collaborative research and development of Klotho gene therapy. This initiative aims to extend human longevity and diminish the impact of age-related diseases. The company maintains its headquarters in Omaha, Nebraska.
Anew Medical, Inc. is most often compared with the following Healthcare names: